Hypoglycemic therapy in patients on hemodialysis and peritoneal dialysis
https://doi.org/10.14341/2072-0351-6064
Abstract
Diabetes mellitus (DM) is a leading cause of renal insufficiency in developed countries. Most cases of chronic renal disease in DM patients are dueto diabetic nephropathy. The impairment of renal function at later stages of diabetic nephropathy is accompanied by complicated changes in the regulationof carbohydrate metabolism most of which require hypoglycemic therapy to be corrected
About the Authors
Irina Arkad'evna Bondar'
Novosibirsk State Medical University, Novosibirsk
Vadim Valer'evich Klimontov
Novosibirsk State Medical University, Novosibirsk
References
1. Sechi L.A., Catena C., Zingaro L. et al. Abnormalities of glucose metabolism in patients with early renal failure // Diabetes. - 2002. - Vol. 51, N 4. - P. 1226-1232.
2. Kobayashi S., Maesato K., Moriya H. et al. Insulin resistance in patients with chronic kidney disease // Am. J. Kidney Dis. - 2005. - Vol. 45, N 2. - P. 275-280.
3. Charlesworth J.A., Kriketos A.D., Jones J.E. et al. Insulin resistance and postprandial triglyceride levels in primary renal disease // Metabolism. - 2005. - Vol. 54, N 6. - P. 821-828.
4. Rave K., Heise T., Pfutzner A. et al. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients // Diabetes Care. - 2001. - Vol. 24, N 5. - P. 886-890.
5. D'Apolito M., Du X., Zong H. et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure // J. Clin. Invest. - 2010. - Vol. 120, N 1. - P. 203-213.
6. Бергер М., Старостина Е.Г., Йоргенс В., Дедов И. Практика инсули- нотерапии. 1-е рус. изд. - Berlin Heidelberg: Springer-Verlag, 1990.
7. Moen M.F., Zhan M., Hsu V.D. et al. Frequency of hypoglycemia and its significance in chronic kidney disease // Clin. J. Am. Soc. Nephrol. - 2009. - Vol. 4, N 6. - P. 1121-1127.
8. Климонтов В.В. Особенности формирования и ранняя диагностика поражения почек у больных сахарным диабетом 1-го типа. Авто- реф. … д-ра мед. наук. - Новосибирск, 2008.
9. Burger A.J., D'Elia J.A., Weinrauch L.A. et al. Marked abnormalities in heart rate variability are associated with progressive deterioration of renal function in type I diabetic patients with overt nephropathy // Int. J. Cardiol. - 2002. - Vol. 86, N 2-3. - P. 281-287.
10. Abe M., Kikuchi F., Kaizu K., Matsumoto K. The influence of hemodialysis membranes on the plasma insulin level of diabetic patients on maintenance hemodialysis // Clin. Nephrol. - 2008. - Vol. 69, N 5. - P. 354-360.
11. Abe M., Kaizu K., Matsumoto K. Plasma insulin is removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose // Ther. Apher. Dial. - 2007. - Vol. 11, N 4. - P. 280-287.
12. Foss M.C., Gouveia L.M., Moysйs Neto M. et al. Effect of hemodialysis on peripheral glucose metabolism of patients with chronic renal failure // Nephron. -1996. -Vol. 73, N 1. - P. 48-53.
13. Руководство по диализу. / Ред.: Дж.Т. Даугирдас, П.Дж. Блэйк, Т.С. Инг. / Пер. с англ. - 3-е изд. - М.: Центр диализа, Тверь: ООО «Издательство «Триада», 2003.
14. Шестакова М. В., Дедов И. И. Сахарный диабет и хроническая болезнь почек. - М.: МИА, 2009. - 482 С.
15. Tascona D.J., Morton A.R., Toffelmire E.B. et al. Adequacy of glycemic control in hemodialysis patients with diabetes // Diabetes Care. - 2006. - Vol. 29, N 10. - P. 2247-2251.
16. Oomichi T., Emoto M., Tabata T. et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study // Diabetes Care. - 2006. - Vol. 29, N 7. - P. 1496-1500.
17. Fukuoka K., Nakao K., Morimoto H. et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis // Nephrology (Carlton). - 2008. - Vol. 13, N 4. - P. 278-283.
18. Ishimura E., Okuno S., Kono K. et al. Glycemic control and survival of diabetic hemodialysis patients - importance of lower hemoglobin A1C levels // Diabetes Res. Clin. Pract. - 2009. - Vol. 83, N 3. - P. 320-326.
19. Shrishrimal K., Hart P., Michota F. Managing diabetes in hemodialysis patients: observations and recommendations // Cleve. Clin. J. Med. - 2009. - Vol. 76, N 11. - P. 649-655.
20. Manley H. J., Allcock N. M. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis // Pharmacotherapy. - 2003. - Vol. 23, N 7. - P. 861-865.
21. Chiang C.K., Ho T.I., Peng Y.S. et al. Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects // Diabetes Care. - 2007. - Vol. 30, N 1. - P. 3-7.
22. Abe M., Kikuchi F., Kaizu K., Matsumoto K. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis // Clin. Nephrol. - 2007. - Vol. 68, N 5. - P. 287-294.
23. Brunelli S.M., Thadhani R., Ikizler T.A., Feldman H.I. Thiazolidinedione use is associated with better survival in hemodialysis patients with non- insulin dependent diabetes // Kidney Int. - 2009. - Vol. 75, N 9. - P. 961-968.
24. Czock D., Aisenpreis U., Rasche F.M., Jehle P.M. Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus // Int. J. Clin. Pharmacol. Ther. - 2003. - Vol. 41, N 10. - P. 492-497.
25. Sobngwi E., Enoru S., Ashuntantang G. et al. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis // Diabetes Care. - 2010. - In press.
26. Jackson M.A., Holland M.R., Nicholas J. et al. Hemodialysis-induced hypoglycemia in diabetic patients // Clin. Nephrol. - 2000. - Vol. 54, N 1. - P. 30-34.
27. Burmeister J.E., Scapini A., da Rosa Miltersteiner D. et al. Glucose- added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis // Nephrol. Dial. Transplant. - 2007. - Vol. 22, N 4. - P. 1184-1189.
28. Rohrscheib M., Tzamaloukas A.H., Ing T.S. et al. Serum potassium concentration in hyperglycemia of chronic dialysis // Adv. Perit. Dial. - 2005. - Vol. 21. - P. 102-105.
29. Cho K.H., Do J.Y., Park J.W., Yoon K.W. Effect of icodextrin dialysis solution on body weight and fat accumulation over time in CAPD patients // Nephrol. Dial. Transplant. - 2010. - Vol. 25, N 2. - P. 593-599.
30. Szeto C.C., Chow K.M., Kwan B.C. et al. New-onset hyperglycemia in nondiabetic chinese patients started on peritoneal dialysis // Am. J. Kidney Dis. - 2007. - Vol. 49, N 4. - P. 524-532.
31. Johnson D.W., Armstrong K., Campbell S.B. et al. Metabolic syndrome in severe chronic kidney disease: prevalence, predictors, prognostic significance and effects of risk factor modification // Nephrology (Carlton). - 2007. - Vol. 12, N 4. - P. 391-398.
32. Gallieni M., Musetti C., Granata A. et al. Metabolic consequences of peritoneal dialysis treatment // Panminerva Med. - 2009. - Vol. 51, N 3. - P. 175-185.
33. Szeto C.C., Chow K.M., Leung C.B. et al. Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis // Nephrol. Dial. Transplant. - 2007. - Vol. 22, N 6. - P. 1697-1702.
34. Gьrsu E.M., Ozdemir A., Yalinbas B. et al. The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients // Clin. Nephrol. - 2006. - Vol. 66, N 4. - P. 263-268.
35. Canbakan M., Sahin G. M. Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients // Ren. Fail. - 2007. - Vol. 29, N 3. - P. 289-293.
36. Paniagua R., Ventura M. D., Avila-Diaz M. et al. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients // Perit. Dial. Int. - 2009. - Vol. 29, N 4. - P. 422-432.
37. Babazono T., Nakamoto H., Kasai K. et al. Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis // Am. J. Nephrol. - 2007. - Vol. 27, N 4. - P. 409-415.
38. Lin S.H., Lin Y.F., Kuo S.W. et al. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD // Am. J. Kidney Dis. - 2003. - Vol. 42, N 4. - P. 774-780.
39. Wong T.Y., Szeto C.C., Chow K.M. et al. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis // Am. J. Kidney Dis. - 2005. - Vol. 46, N 4. - P. 713-719.
40. van Hooland S., Boey O., Van der Niepen P. et al. Effect of short-term rosiglitazone therapy in peritoneal dialysis patients // Perit. Dial. Int. - 2009. - Vol. 29, N 1. - P. 108-111.
41. Dasgupta M.K. Strategies for managing diabetic patients on peritoneal dialysis // Adv. Perit. Dial. - 2004. - Vol. 20. - P. 200-202.
42. Mehmet S., Quan G., Thomas S., Goldsmith D. Important causes of hypoglycaemia in patients with diabetes on peritoneal dialysis // Diabet. Med. - 2001. - Vol. 18, N 8. - P. 679-682.
43. Williams J.D., Craig K.J., Topley N. et al. Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease // J. Am. Soc. Nephrol. - 2002. - Vol. 13. - P. 470-479.
44. Stoenoiu M.S., De Vriese A.S., Brouet A. et al. Experimental diabetes induces functional and structural changes in the peritoneum // Kidney Int. - 2002. - Vol. 62, N 2. - P. 668-678.
45. De Vriese A.S., Flyvbjerg A., Mortier S. et al. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane // J. Am. Soc. Nephrol. - 2003. - Vol. 14, N 8. - P. 2109-2118.
46. Selgas R., Diez J.J., Munoz J. et al. Comparative study of two different routes for insulin administration in CAPD diabetic patients. A multicenter study // Adv. Perit. Dial. - 1989. - Vol. 5. - P. 181-184.
47. Tzamaloukas A.H., Oreopoulos D.G. Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: a review // Adv. Perit. Dial. - 1991. - Vol. 7. - P. 81-85.
48. Nevalainen P., Lahtela J.T., Mustonen J., Pasternack A. The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients // Nephrol. Dial. Transplant. - 1997. - Vol. 12, N 1. - P. 145-150.
49. Quellhorst E. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration // J. Am. Soc. Nephrol. - 2002. - Vol. 13, Suppl. 1. - P. S92-S96.
50. Widerшe T.E., Dahl K.J., Smeby L.C. et al. Pharmacokinetics of transperitoneal insulin transport // Nephron. - 1996. - Vol. 74, N 2. - P. 283-290.
51. Wanless I.R., Bargman J.M., Oreopoulos D.G. et al. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity // Mod. Pathol. - 1989. - Vol. 2. - P. 69-74.
52. Torun D., Oguzkurt L., Sezer S. et al. Hepatic subcapsular steatosis as a complication associated with intraperitoneal insulin treatment in diabetic peritoneal dialysis patients // Perit. Dial. Int. - 2005. - Vol. 25, N 6. - P. 596-600.
53. Nevalainen P.I., Kallio T., Lahtela J.T. et al. High peritoneal permeability predisposes to hepatic steatosis in diabetic continuous ambulatory peritoneal dialysis patients receiving intraperitoneal insulin // Perit. Dial. Int. - 2000. - Vol. 20, N 6. - P. 637-642.
Review
For citations:
Bondar' I.A., Klimontov V.V. Hypoglycemic therapy in patients on hemodialysis and peritoneal dialysis. Diabetes mellitus. 2010;13(4):87-92. (In Russ.) https://doi.org/10.14341/2072-0351-6064
Views:
15925
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
